GlassScriptPhysician profile
Neeraj Kumar Sharma
NPI 1841304458
$9,226.98
in general payments reported to CMS, 2019-2025
41 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $794 · 2021: $1,488 · 2022: $1,480 · 2023: $1,830 · 2024: $977 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.27 |
| Education | $143.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,444.78 | 2019-2025 | Linzess, Skyrizi, Creon |
| Janssen Biotech, INC. | $905.48 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $844.51 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $790.21 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Ardelyx, INC. | $409.85 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $378.28 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $364.13 | 2019-2025 | |
| Genzyme Corporation | $353.17 | 2022-2025 | |
| Medtronic, INC. | $277.20 | 2021-2024 | Interstim, Gi Genius, Nexpowder |
| Celgene Corporation | $249.47 | 2019-2024 | Zeposia |
| Pfizer INC. | $175.54 | 2019-2025 | |
| Daiichi Sankyo INC. | $161.10 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $156.12 | 2019-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $146.86 | 2023-2025 | Dupixent |
| Covidien LP | $145.83 | 2020 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $131.03 | 2019-2022 | |
| Ucb, INC. | $127.74 | 2019-2021 | |
| Amgen INC. | $125.68 | 2020-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $125.66 | 2024-2025 | Omvoh, Zepbound |
| United Therapeutics Corporation | $125.00 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $82.03 | 2024-2025 | Iqirvo |
| Olympus America INC. | $75.25 | 2019-2023 | Evis Exera Lll Colonovideoscope |
| E.R. Squibb & Sons, L.L.C. | $58.72 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $57.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $56.34 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $54.29 | 2022-2024 | Linzess |
| Celltrion USA INC. | $49.22 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $42.76 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $38.12 | 2023 | Idacio |
| Boston Scientific Corporation | $37.53 | 2024-2025 | Watchman Flx |
| Janssen Scientific Affairs, LLC | $32.03 | 2023 | Stelara |
| Allergan, INC. | $30.96 | 2019 | |
| Braintree Laboratories, INC. | $30.41 | 2021 | |
| Nestle Healthcare Nutrition INC. | $28.01 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.47 | 2023 | |
| Mauna Kea Technologies, INC. | $20.84 | 2023 | |
| Vivus LLC | $16.43 | 2021 | |
| Ethicon US, LLC | $15.00 | 2021 | |
| Alfasigma USA, INC. | $13.72 | 2020 | |
| Redhill Biopharma INC. | $13.51 | 2020 | |
| Aimmune Therapeutics, INC. | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.